A number of research firms have changed their ratings and price targets for DaVita HealthCare Partners (NYSE: DVA):

  • 8/5/2017 – DaVita HealthCare Partners was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/3/2017 – DaVita HealthCare Partners had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $70.00 price target on the stock.
  • 8/3/2017 – DaVita HealthCare Partners was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Over the past one year, DaVita has underperformed the broader industry in terms of price.DaVita ended second-quarter fiscal 2017 on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate while revenues beat the same. Davita’s revenues in the second quarter reflected significant year-over-year growth on the back of strong patient services. The company saw solid improvement in Kidney care in the quarter. DaVita also made efforts to control expenses in the second quarter. The company’s strength basically lies in its enhanced service offerings. A compelling inorganic growth story supported by its strong financial position is another positive. However, DaVita remains challenged by high debt levels, adverse effects of healthcare reforms, rise in Medicare costs, and an increase in Medicare Advantage (MA) beneficiaries. Also, MA rate cuts are likely to hurt the bottom line in the near future.”
  • 8/2/2017 – DaVita HealthCare Partners was downgraded by analysts at TheStreet from a “b” rating to a “c+” rating.
  • 7/8/2017 – DaVita HealthCare Partners was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/4/2017 – DaVita HealthCare Partners was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Over the past one year, DaVita has underperformed the broader industry in terms of price.DaVita ended first-quarter fiscal 2017 on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate while revenues beat the same. Davita’s revenues in the first quarter reflected significant year-over-year growth on the back of strong patient services. The company saw solid improvement in Kidney care in the quarter. DaVita also made efforts to control expenses in the first quarter. The company’s strength basically lies in its enhanced service offerings. A compelling inorganic growth story supported by its strong financial position is another positive. However, DaVita remains challenged by high debt levels, adverse effects of healthcare reforms, rise in Medicare costs, and an increase in Medicare Advantage (MA) beneficiaries. Also, MA rate cuts are likely to hurt the bottom line in the near future.”
  • 6/26/2017 – DaVita HealthCare Partners was downgraded by analysts at Jefferies Group LLC from a “buy” rating to a “hold” rating. They now have a $70.00 price target on the stock, up previously from $64.89.

DaVita HealthCare Partners Inc. (NYSE DVA) traded down 0.69% during trading on Thursday, reaching $56.13. 1,579,925 shares of the company were exchanged. The firm’s 50 day moving average price is $63.37 and its 200-day moving average price is $65.78. The stock has a market capitalization of $10.73 billion, a price-to-earnings ratio of 8.55 and a beta of 0.89. DaVita HealthCare Partners Inc. has a one year low of $54.50 and a one year high of $70.56.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 1st. The company reported $0.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the business posted $1.01 EPS. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, equities research analysts predict that DaVita HealthCare Partners Inc. will post $3.57 earnings per share for the current year.

In related news, CEO Javier Rodriguez sold 1,294 shares of the business’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $66.21, for a total value of $85,675.74. Following the sale, the chief executive officer now directly owns 99,111 shares in the company, valued at approximately $6,562,139.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.10% of the company’s stock.

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Receive News & Ratings for DaVita HealthCare Partners Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.